Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma

Published:August 30, 2022DOI:

      Clinical Practice Points

      • Peritoneal mesothelioma is much rarer than its pleural counterpart; hence, there is a paucity of data to guide management, which usually follows guidelines available for pleural mesothelioma, despite reported molecular differences between the 2 anatomic sites.
      • A recent randomized clinical trial demonstrated better response rate, progression-free survival and overall survival with dual immunotherapy (ipilimumab and nivolumab) than with cytotoxic chemotherapy in pleural mesothelioma.
      • The clinical and radiological response observed with dual immunotherapy in a patient with peritoneal mesothelioma suggests that this a promising therapeutic approach.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Teta MJ
        • Mink PJ
        • Lau E
        • Sceurman BK
        • Foster ED.
        US mesothelioma patterns 1973-2002: indicators of change and insights into background rates.
        Eur J Cancer Prev. 2008; 17: 525-534
        • Henley SJ
        • Larson TC
        • Wu M
        • et al.
        Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008.
        Int J Occup Environ Health. 2013; 19: 1-10
        • Baas P
        • Scherpereel A
        • Nowak AK
        • et al.
        First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
        Lancet. 2021; 397: 375-386
        • Becker O
        • Beaulaton C
        • Masliah-Planchon J
        • Servois V
        • Watson S.
        Nivolumab activity in advanced refractory malignant peritoneal mesothelioma.
        Eur J Cancer. 2021; 144: 386-388
        • Tanaka T
        • Miyamoto Y
        • Sakai A
        • Fujimoto N.
        Nivolumab for malignant peritoneal mesothelioma.
        BMJ Case Rep. 2020; 13: e237721
        • Husain AN
        • Colby TV
        • Ordóñez NG
        • et al.
        Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group.
        Arch Pathol Lab Med. 2018; 142: 89-108
        • Shrestha R
        • Nabavi N
        • Lin YY
        • et al.
        BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
        Genome Med. 2019; 11: 8